FLAGSTAFF, Ariz. (January 10, 2025) — W. L. Gore & Associates Medical Products (Gore) today announced the first commercial use of the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System in Canada.

The news coincides with Health Canada approval of the device for the treatment of abdominal aortic aneurysm (AAA) patients with aortic landing zones as short as 10 mm and neck angulation up to 90°.

Combining exceptional conformability with a delivery system fine-tuned for precision, the device offers physicians a new degree of control and a novel solution for highly angulated aortic necks.

“With the conformability of its nested stent design, angulation control and two-stage deployment, the GORE® EXCLUDER® Conformable AAA Device gives us the only option for endovascular repair of difficult angulated anatomy,” remarked Kevin Lee, M.D., who used the device commercially for the first time.

“We can reconstrain. We can reposition. And we can refine angulation,” he continued. “That means more control, more precision and more opportunities to achieve optimal seal.”

“Today was a major milestone for the tools and techniques at our disposal, and it built on the performance we’ve come to rely on over the years using the GORE® EXCLUDER® Device family.”

“That really is a rare recipe for confidence with a new device,” he concluded.

For Gore Medical Global Aortic Business Leader, Willy Davison, today’s announcement “signals our continuing, core commitment to extend the global reach of our endovascular treatments.”

“Progress doesn’t happen overnight,” Davison continued. “It takes years of work from countless contributors whose ideas and energy infuse the very fabric of our products. This device and delivery system are the culmination of decades of deep collaboration with physicians aimed at understanding and overcoming treatment challenges in aneurysmal disease.”

“We’re delighted to deliver this device for physicians in Canada,” Davison added, “and, above all, for the patients in their care.”